Key result
Vutrisiran reduces mortality and recurrent cardiovascular events ~29% regardless of background therapy.
Why the study?
Whether concomitant disease-modifying or heart failure therapy modifies the efficacy of vutrisiran in patients with transthyretin amyloid cardiomyopathy has not been described.
Does concomitant use or postrandomization initiation of tafamidis or heart failure therapies modify the efficacy of vutrisiran on all-cause mortality and recurrent cardiovascular events in patients with ATTR-CM?
RCT (n=654)
Double-blind
Randomized (post hoc subgroup/time-updated analysis of HELIOS-B)
Yes
Does concomitant use or postrandomization initiation of tafamidis or heart failure therapies modify the efficacy of vutrisiran on all-cause mortality and recurrent cardiovascular events in patients with ATTR-CM?
Vutrisiran consistently reduces all-cause mortality and recurrent cardiovascular events in ATTR-CM regardless of baseline or newly initiated concomitant tafamidis or heart failure therapies.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“support the consistency of vutrisiran's treatment effect across the spectrum of contemporary ATTR-CM pharmacotherapy and provide evidence for its use alongside other disease-modifying and guideline-directed HF therapies in clinical practice.”
Supports vutrisiran addition to ATTR-CM regimens irrespective of tafamidis or HF therapy; extends HELIOS-B efficacy to contemporary polypharmacy.
BACKGROUND: Vutrisiran, an RNA interference therapeutic, reduced all-cause mortality and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the HELIOS-B trial. Whether concomitant disease-modifying or heart failure therapy modifies the efficacy of vutrisiran has not been described. OBJECTIVES: We aimed to characterize patterns of concomitant therapy use in HELIOS-B, describe medication initiation rates by treatment arm, and evaluate whether concomitant therapy modified vutrisiran's treatment effect. METHODS: In HELIOS-B, 654 randomized patients with ATTR-CM received vutrisiran or placebo. We assessed baseline use and postrandomization initiation of tafamidis, sodium-glucose cotransporter-2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRA), beta-blockers, and renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors), and used time-updated Lin-Wei-Yang-Ying models to evaluate treatment effect modification on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events. RESULTS: At baseline, 40% of participants were receiving tafamidis and 77% at least 1 heart failure medication. MRAs and SGLT2 inhibitors were the most frequently initiated therapies during follow-up, with initiation rates numerically higher across all heart failure medication classes in the placebo group. There was no statistically significant evidence that the treatment effect of vutrisiran was modified by baseline or time-updated use of any medication class (P-interaction: tafamidis 0.95, SGLT2 inhibitors 0.59, MRA 0.92, beta-blockers 0.75, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors 0.82). CONCLUSIONS: In HELIOS-B, there was no statistically significant evidence that the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events was modified by concomitant use of tafamidis or heart failure therapies. These findings support the consistency of vutrisiran's efficacy across the spectrum of contemporary ATTR-CM pharmacotherapy. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Abovich et al. (2026) conducted an RCT in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=654). Vutrisiran vs. Placebo (across baseline and time-updated concomitant tafamidis and heart failure medication strata) was evaluated on Composite of all-cause mortality and recurrent cardiovascular events (hospitalizations for cardiovascular causes or urgent heart failure visits) (RR 0.71, 95% CI 0.54-0.92, p=0.95 for interaction with tafamidis). Vutrisiran reduced all-cause mortality and recurrent cardiovascular events without modification by tafamidis or HF therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: